Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

While allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potential curative therapy against hematological malignancies, modulation of donor T cell alloreactivity is required to enhance the graft-versus-leukemia (GVL) effect and control graft-versus-host-disease (GVHD) after allo-HSCT. Donor-derived regulatory CD4CD25Foxp3 T cells (Tregs) play a central role in establishing of immune tolerance after allo-HSCT. They could be a key target to be modulated for increasing the GVL effect and control of GVHD. We constructed an ordinary differential equation model incorporating bidirectional interactions between Tregs and effector CD4 T cells (Teffs) as a mechanism for control of Treg cell concentration. The goal is to elucidate how the interaction between Tregs and Teffs is modulated in order to get insights into fine tuning of alloreactivity after allo-HSCT. The model was calibrated with respect to published Treg and Teff recovery data after allo-HSCT. The calibrated model exhibits perfect or near-perfect adaptation to stepwise perturbations between Treg and Teff interactions, as seen in Treg cell populations when patients with relapsed malignancy were treated with anti-CTLA-4 (cytotoxic T lymphocyte-associated antigen 4). In addition, the model predicts observed shifts of Tregs and Teffs concentrations after co-stimulatory receptor IL-2R or TNFR2 blockade with allo-HSCT. The present results suggest simultaneous blockades of co-stimulatory and co-inhibitory receptors as a potential treatment for enhancing the GVL effect after allo-HSCT without developing GVHD.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biosystems.2023.104889DOI Listing

Publication Analysis

Top Keywords

donor-derived regulatory
8
allogeneic hematopoietic
8
hematopoietic stem
8
stem cell
8
cell transplantation
8
gvl control
8
treg cell
8
tregs teffs
8
treg teff
8
allo-hsct
7

Similar Publications

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) offers a potential cure for hematologic malignancies, but post-transplant complications, particularly graft--host disease (GVHD), remain major challenges. Regulatory T cells and interleukin-10 () play key roles in immune regulation. This retrospective study investigated the impact of donor -3279 (rs3761548) and -819 (rs1800871) single-nucleotide polymorphisms (SNPs) on clinical outcomes in 92 allo-HSCT recipients, with emphasis on umbilical cord blood transplantation (UCBT).

View Article and Find Full Text PDF

Background: Operational tolerance, defined as stable liver graft function without immunosuppression, has been observed in select transplant recipients. While immune regulatory mechanisms have been implicated, the biological processes underlying tolerance remain incompletely understood. Notably, recipient-derived hepatocytes have been shown to progressively repopulate donor livers, raising the possibility that this histological change may contribute to tolerance induction.

View Article and Find Full Text PDF

Neurotoxicity associated with chimeric antigen receptor T-cell therapy.

J Neuroimmunol

October 2025

Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, VIC, Australia; Department of Neurology, Alfred Health, Melbourne, VIC, Australia. Electronic address:

Chimeric antigen receptor T cell (CAR-T) therapy involves reengineering patient-derived or donor-derived T cells to express a synthetic CAR that can recognise specific cell-surface antigens, independently of major histocompatibility complex molecules. As of March 2025, six autologous CAR-T cell products have received regulatory approval from the United States Food and Drug Administration (FDA) for B-cell derived haematological malignancies and multiple myeloma, delivering effective and durable treatment responses. All currently approved CAR-T cell therapy products target either CD19 or B-cell maturation antigen (BCMA).

View Article and Find Full Text PDF

Background: Chimeric Antigen Receptor T cell (CAR-T) therapy is a groundbreaking, personalized immunotherapy that genetically engineers patient or donor-derived T cells to recognize and eliminate cancer cells. The U.S FDA has approved six CAR-T cell products in the past decade.

View Article and Find Full Text PDF

Background: Vascularized composite allotransplantation (VCA) offers a promising solution for restoring function in patients with severe tissue trauma, yet acute rejection remains a major hurdle. Acute rejection is driven by an immune response against transplanted tissues, requiring lifelong immunosuppression, increasing risks of infections, malignancies, and organ toxicity. This study aims to develop a mouse hindlimb transplant model to investigate immune responses and the phenotype of infiltrating cells in these grafts.

View Article and Find Full Text PDF